Efficacy of entecavir in the treatment of patients with chronic hepatitis B and cirrhosis

Objective To investigate the effectacy of entecavir in the treatment of patients with chronic hepatitis B and cirrhosis.Methods Thirty-four patients with chronic hepatitis B and twenty-four patients with HBV-induced liver cirrhosis took ETV 0.5mg/d orally for 96 weeks.Results In the CHB group,the rates of HBV DNA negativity at week 12,24,48 and 96 were 61.76%(21/34),82.35%(28/34),94.12%(32/34)and 94.12%(32/34,P0.05),respectively;and in the LC group,they were 72.73%(16/22),81.82%(18/22),81.82%(18/22)and 90.91%(20/22,P0.05),respectively;At week 12,the levels of serum ALT were significantly decreased(P0.05).No side effect was observed in the patients during treatment.Conclusion ETV is effective and safe in treatment of patients with chronic hepatitis B and with HBV-induced liver cirrhosis.